Generate Life Sciences→CooperSurgical (CooperCompanies)
Acquisition · Cash · COO · announced Nov 10, 2021
Announced
Nov 10, 2021
Closed
Jan 31, 2022
Economics
Cash()
Pre-deal · pre-deal mark: 2021, year precision · rounding grid ±$100M · CooperSurgical press release — acquisition coverage, 2022
~$1.6B (CooperCompanies press release)
Target
Generate Life Sciences
Reproductive Health · Fertility science
HQ Los Angeles, CA · Founded 2020
Donor egg and sperm for fertility, cryopreservation services, and newborn stem cell storage (cord blood and tissue)
- CooperCompanies investor relations - press release (Nov 10, 2021)
- Globe Newswire - acquisition announcement
Acquirer
CooperSurgical (CooperCompanies) (COO)
Fertility
HQ Trumbull, CT
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Expanded fertility and L&D offerings with donor egg/sperm, cryopreservation, and cord blood storage — ~$250M trailing revenue
Evidence ladder
Secondary (press / IR)
CooperCompanies investor relations — Globe Newswire (Nov 10, 2021)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/711404/000119312521326207/d204711d8k.htm
Open source
Limitations
- ~$1.6B (CooperCompanies press release)
- Pre-deal valuation sourced from: CooperSurgical press release — acquisition coverage, 2022. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Reproductive Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Myovant Sciences | Sumitovant Biopharma (Sumitomo Pharma) | Oct 24, 2022 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Forendo Pharma | Organon | Nov 11, 2021 |
Other verified deals by CooperSurgical (CooperCompanies)
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| obp Surgical | CooperSurgical (CooperCompanies) | Aug 1, 2024 | Gynecological Surgery | |
| ZyMōt Fertility | CooperSurgical | Jun 10, 2024 | Undisclosed | Fertility |
| Cook Medical Reproductive Health | CooperSurgical (CooperCompanies) | Feb 7, 2022 | Undisclosed | Fertility |
| ORIGIO a/s | CooperSurgical (CooperCompanies) | Jun 4, 2012 | Fertility |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Generate Life Sciences (Reproductive Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.